Clinical Trials Logo

Filter by:
NCT ID: NCT02054871 Recruiting - Clinical trials for Peripheral Vascular Disease

RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty

Start date: September 2013
Phase: N/A
Study type: Interventional

This study aims to demonstrate if remote ischaemic preconditioning (RIPC) may confer renal protection in patients undergoing peripheral angioplasty. Patients will be randomised to receive RIPC and biomarkers for renal injury will be analysed post procedure to determine if any protective benefit was obtained.

NCT ID: NCT02054858 Recruiting - Acute Kidney Injury Clinical Trials

Preconditioning Against Renal Damage Under Contrast Examination

Re-DUCE-F
Start date: January 2014
Phase: N/A
Study type: Interventional

This study aims to assess if applying an ischaemic insult to an arm before giving intravenous contrast will help decrease the incidence of developing contrast induced acute renal injury in patients undergoing contrast-enhanced CT Scans. The main research question is 'In adult in-patients undergoing contrast-enhanced CT scans, does remote ischaemic pre-conditioning (RIPC) induced by brief arm ischaemia and reperfusion, when compared to control, reduce the proportion of patients developing contrast-induced acute kidney injury in the first 3 post-scan days? '.

NCT ID: NCT02051348 Completed - Clinical trials for HELICOBACTER INFECTION

Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion

Start date: January 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Helicobator pylori (H. pylori) is a bacteria which survives in the lining of the stomach. An estimated 50% of the world's population is infected with H. pylori. Developing economies, such as in Southeast Asia, the Indian subcontinent and Latin America, have prevalence rates of as high as 90%. H. pylori infection often goes undiagnosed, as many sufferers do not experience any adverse symptoms. Infection with H. pylori is described as "not a disease in itself but a condition that affects the relative risk of developing various clinical disorders of the upper gastrointestinal tract.' Clinically relevant symptoms could include peptic ulcer, melena or secondary conditions such as iron deficiency anemia or vitamin B12 deficiency. There is evidence that probiotics can be beneficial for those with gastrointestinal diseases. Pylopass contains the probiotic strain Lactobacillus reuteri, which was selected for its anti-H. pylori characteristics and in clinical trials has shown to result in a reduction in urease breath test values in subjects with H. pylori. The objective of this study is to evaluate the ability of Pylopass to reduce H. pylori load in subjects who are H. pylori positive.

NCT ID: NCT02051010 Completed - Clinical trials for Metastatic Breast Cancer

ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?

Start date: May 2013
Phase: N/A
Study type: Observational

The study will follow a descriptive design involving a survey. Data collection will involve paper based questionnaires. The questionnaires have been developed in conjunction with breast cancer support groups associated with the Irish Cancer Society and patients.

NCT ID: NCT02050997 Terminated - Clinical trials for Pancreatic Ductal Adenocarcinoma

Plasma Biomarkers P-DAC, V1

Start date: May 26, 2014
Phase:
Study type: Observational

This is an exploratory, translational, non-interventional and multi-centre clinical study. The aim of the study is to identify predictive plasma biomarkers of response to chemotherapy in PDAC.

NCT ID: NCT02050750 Active, not recruiting - Breast Cancer Clinical Trials

TAILORx Tissue Bank

Start date: December 2013
Phase:
Study type: Observational

This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.

NCT ID: NCT02050737 Terminated - Colorectal Cancer Clinical Trials

Plasma Biomarkers C-RAC, ICORG 12-27, V1

Start date: October 2013
Phase:
Study type: Observational

This is an exploratory, translational, non-interventional and multi-centre clinical study.

NCT ID: NCT02047097 Completed - Multiple Sclerosis Clinical Trials

Dimethyl Fumarate (DMF) Observational Study

ESTEEM
Start date: November 19, 2013
Phase:
Study type: Observational [Patient Registry]

The primary objective of the study is to determine the incidence, type, and pattern of serious adverse events (SAEs), including but not limited to infections (including opportunistic infections), hepatic events, malignancies, and renal events, and of adverse events (AEs) leading to treatment discontinuation in patients with MS treated with dimethyl fumarate (DMF). Secondary objectives of this study in this population are as follows: To determine dimethyl fumarate (DMF) prescription and utilization patterns in routine clinical practice in patients with multiple sclerosis (MS); To assess the effectiveness of dimethyl fumarate (DMF) on multiple sclerosis (MS) disease activity and disability progression in routine clinical practice as determined by the Expanded Disability Status Scale (EDSS) score and multiple sclerosis (MS) relapse information; and To assess the effect of dimethyl fumarate (DMF) on health-related quality of life, healthcare resource consumption, and work productivity.

NCT ID: NCT02041806 Recruiting - Clinical trials for Complication of Anesthesia

Assessing Peripheral Nerve Block Scoring Systems for Intra-Operative and Post-Operative Analgesia

Start date: July 2013
Phase: N/A
Study type: Observational

The purpose of this study is to determine if Peripheral Nerve Block scoring systems are effective in predicting the achievement of intra-operative anaesthesia and post-operative analgesia.

NCT ID: NCT02040714 Enrolling by invitation - Clinical trials for Legg Calve Perthes Disease

Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease

IPSG1
Start date: August 2012
Phase:
Study type: Observational

Legg-Calvé-Perthes disease is a childhood hip disorder which is common enough to be a significant public health problem (affects 1 in 740 boys between ages 0-14), but uncommon enough to have a sufficient number of patients from a single institution to perform a definitive prospective study comparing the results of current treatments. The present study will establish a database of prospectively identified patients with Legg-Calvé-Perthes (LCP) Disease and collect information regarding their presentation, treatment, and outcomes in the course of receiving currently available treatments. This study seeks to compare the outcomes of current treatments in the management of different age groups (ages 1-6, 6-8, 8-11, >11) of patients with Perthes disease at two- and five-year followup and at skeletal maturity. For each age group, two to three common treatment regimens currently used by practicing pediatric orthopaedic surgeons will be compared. The intervention a patient receives is determined through physician treatment expertise, and is not pre-determined by the study.